Previous Close | 6.44 |
Open | 6.58 |
Bid | 6.28 x 900 |
Ask | 6.40 x 1000 |
Day's Range | 6.45 - 6.58 |
52 Week Range | 6.01 - 8.90 |
Volume | |
Avg. Volume | 16,253 |
Market Cap | 35.914M |
Beta (5Y Monthly) | 0.77 |
PE Ratio (TTM) | 90.00 |
EPS (TTM) | 0.07 |
Earnings Date | Mar 21, 2022 - Mar 25, 2022 |
Forward Dividend & Yield | 0.20 (2.74%) |
Ex-Dividend Date | Dec 17, 2021 |
1y Target Est | N/A |
ACTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2022, and the declaration of a cash dividend of $0.07 per share to be paid on June 24, 2022, to shareholders of record as of May 27, 2022. The Company’s revenue for the quarter ended March 31, 2022, was $6.5 million versus $5.7 million for the quarter ended March 31, 2021, an
Investors who take an interest in Psychemedics Corporation ( NASDAQ:PMD ) should definitely note that insider Peter...
ACTON, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced today fourth quarter and full year financial results for the period ended December 31, 2021. The Company’s revenue for the year ended December 31, 2021, was $24.9 million versus $21.4 million for the year ended December 31, 2020, an increase of 17%. Net loss for the year ended December 31, 2021, was $0.7 million or $0.12 per diluted s